Formation of Supramolecular Activation Clusters on Fresh Ex Vivo CD8+ T Cells After Engagement of the T Cell Antigen Receptor and CD8 by Antigen-presenting Cells
Overview
Authors
Affiliations
Upon productive interaction of CD4 T cells with antigen-presenting cells (APCs), receptors and intracellular proteins translocate and form spatially segregated supramolecular activation clusters (SMACs). It is not known whether SMACs are required for CD8 T cell activation. CD8 T cells, unlike CD4 T cells, can be activated by a single peptide-MHC molecule, or by purified monovalent recombinant peptide-MHC molecules. We studied, by three-dimensional digital microscopy, cell conjugates of fresh ex vivo CD8 T cells (obtained from OT-1 mice, which are transgenic for T cell antigen receptor reactive with the complex of H-2K(b) and the ovalbumin octapeptide SIINFEKL) and peptide-pulsed APCs. Remarkably, even in T cell:APC conjugates that were formed in the presence of the lowest concentration of peptide that was sufficient to elicit T cell proliferation and IFN-gamma production; the theta isoform of protein kinase C was clustered in a central SMAC, and lymphocyte function-associated antigen 1 and talin were clustered in the peripheral SMAC. Conjugation of T cells to APCs that were pulsed with concentrations of peptide smaller than that required to activate T cells was greatly reduced, and SMACs were not formed at all. APCs expressing mutant H-2K(b) (Lys(227)) molecules that do not bind CD8 were unable to form stable conjugates with these T cells, even at high peptide concentrations. Thus, although CD8 and CD4 T cells may display different sensitivity to the concentration and oligomerization of surface receptors, SMACs are formed and seem to be required functionally in both cell types. However, unlike CD4 T cells, which can form SMACs without CD4, CD8 T cells from OT-1 transgenic mice depend on their coreceptor, CD8, for the proper formation of SMACs.
Lingel H, Fischer L, Remstedt S, Kuropka B, Philipsen L, Han I Cell Death Differ. 2024; 32(3):561-572.
PMID: 39390117 PMC: 11893764. DOI: 10.1038/s41418-024-01399-y.
Forks in the road for CAR T and CAR NK cell cancer therapies.
Dagher O, Posey Jr A Nat Immunol. 2023; 24(12):1994-2007.
PMID: 38012406 DOI: 10.1038/s41590-023-01659-y.
Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".
Teppert K, Wang X, Anders K, Evaristo C, Lock D, Kunkele A Int J Mol Sci. 2022; 23(23).
PMID: 36498890 PMC: 9739809. DOI: 10.3390/ijms232314563.
Pineau J, Pinon L, Mesdjian O, Fattaccioli J, Dumenil A, Pierobon P Elife. 2022; 11.
PMID: 36111670 PMC: 9592083. DOI: 10.7554/eLife.78330.
The role of protease-activated receptor 1 signaling in CD8 T cell effector functions.
Chen H, Smith M, Herz J, Li T, Hasley R, Le Saout C iScience. 2021; 24(11):103387.
PMID: 34841225 PMC: 8605340. DOI: 10.1016/j.isci.2021.103387.